20/20 Biolabs, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
20/20 Biolabs filed a Third Amended and Restated Certificate of Incorporation on September 16, 2026, increasing authorized common stock to 500M shares (from unspecified prior amount) and authorized preferred stock to 20M shares, both at $0.01 par value. The amendment includes standard Delaware governance provisions (director liability limitations, indemnification, opportunity renunciation for non-employee directors). No material financial transactions, capital raises, or operational changes are disclosed in this filing.
Why this rating
Routine corporate governance amendment; no business impact, capital raise, or operational change disclosed. Standard authorized share increase for a micro-cap biolab.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.